Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.
Medigus Ltd. (MDGS) pioneers minimally invasive endoscopic solutions for gastrointestinal disorders, with its flagship SRS system transforming GERD treatment. This dedicated news hub provides investors and medical professionals with timely updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access comprehensive coverage of Medigus’ developments including product launches, clinical trial results, financial performance, and OEM manufacturing initiatives. Our curated repository ensures stakeholders stay informed about innovations in endoscopic stapling systems, ultrasonic alignment technologies, and collaborative healthcare projects.
Key updates feature progress in endoluminal procedures, manufacturing expansions, and intellectual property achievements. Regular updates include earnings reports, executive leadership changes, and research breakthroughs that underscore Medigus’ position in medical device innovation.
Bookmark this page for direct access to official press releases and objective analysis of Medigus’ contributions to minimally invasive surgery. Check regularly for verified updates on the company’s progress in redefining endoscopic intervention standards and expanding global healthcare partnerships.
Medigus Ltd. (Nasdaq: MDGS) reported a record revenue of $10.1 million for fiscal year 2021, marking an increase of 1,805% from $0.5 million in 2020. The company achieved a net income of $4 million, a significant turnaround from a $6.9 million net loss in the prior year. Cash and cash equivalents rose to $24 million at year-end 2021. Shareholders' equity surged 114% to $49 million. Medigus plans to consolidate financial results from Gix Internet, which reported $45 million in revenue for 2021, further enhancing growth potential.
Medigus Ltd. (Nasdaq: MDGS) announced a partnership between its 40% owned ParaZero Ltd. and a global automotive manufacturer to develop a custom safety solution for drones. This agreement involves integrating ParaZero’s SafeAir™ safety system into the manufacturer’s drone program from the design phase. ParaZero has successfully provided safety solutions across various drone platforms and holds ASTM F3322-18 compliant parachute recovery systems, ensuring compliance and reliability for advanced drone operations.
Medigus Ltd. (MDGS) announced a strategic investment of $300,000 in ABI Energy Ltd., representing approximately 19.17% ownership. This investment is part of a $1.4 million funding round aimed at enhancing fluid transportation technology to optimize the global water, oil, and gas infrastructure. ABI, set to be rebranded as Laminera, utilizes innovative technology to reduce pump energy consumption by up to 25% while improving flow capacity. Medigus will also issue $400,000 worth of its American Depositary Shares to ABI, further solidifying its position in this emerging market.
Medigus Ltd. (Nasdaq: MDGS) announces Polyrizon Ltd.'s pre-clinical data indicating its PL-15 product candidate effectively reduces infection rates of the Omicron variant BA.1 in cell culture assays. PL-15 demonstrated substantial protective effects against SARS-CoV-2, validated by viral load quantification and cell mortality methods. These findings support the potential of Polyrizon's C&C™ technology as a preventative solution for various respiratory viruses, building on previous successes with Influenza H1N1 and Human coronavirus 229E.
Medigus Ltd. (Nasdaq: MDGS) announces a significant advancement in drone technology through its 40% ownership in ParaZero Ltd. The FAA has published final airworthiness criteria, allowing leading drone manufacturer Airobotics to progress toward type certification of its automated drone system. This certification marks a major milestone as it establishes the first regulatory pathway for commercial drones in the USA. ParaZero's patented safety system, including a smart parachute that activates autonomously in emergencies, enhances safety and reliability for urban drone operations.
Medigus Ltd. (Nasdaq: MDGS) plans to consolidate the financial results of its affiliate Gix Internet for 2022. Gix reported a 19% revenue increase in 2021, reaching $45.2 million, attributed to its acquisition of Cortex Media. However, Gix faced an operating loss of $0.8 million and a net loss of $1.5 million for the year. Despite this, cash and cash equivalents rose by 38% to $5.4 million, with shareholders' equity increasing over 21%. Medigus expects Gix's performance to positively impact its revenues and balance sheet.
Medigus Ltd. (Nasdaq: MDGS) announced that ParaZero, in which it holds a 40% stake, received a purchase order for its patented SafeAir system from a prominent global drone manufacturer. The integration of SafeAir technology aims to enhance drone safety by autonomously deploying a parachute during malfunctions, potentially saving operators millions. ParaZero's safety system has been adopted by leading companies and is compliant with ASTM F3322-18 standards, allowing advanced drone operations. The small drone shipment market is projected to reach USD $85 billion by 2025.
Medigus Ltd. (Nasdaq: MDGS) has signed a non-binding letter of intent to execute a reverse merger with Fuel Doctor, Inc. (OTC: FDOC). This transaction will make Charging Robotics, a subsidiary of Medigus, a wholly owned part of Fuel Doctor, with Medigus acquiring 80% of Fuel Doctor's outstanding shares. Fuel Doctor is expected to have a minimum of $1 million in net cash at closing. Charging Robotics aims to enhance electric vehicle charging through an automatic wireless charging platform.
Medigus Ltd. (Nasdaq: MDGS) announced that Revoltz, in which it holds a 19.9% stake, will launch a pilot project at a new autonomous supermarket in Israel.
The project includes a purchase order for Revoltz's PORTO micro-mobility vehicle designed for last-mile delivery. With the global last-mile delivery market projected to grow from $108 billion in 2020 to over $200 billion by 2027, Medigus positions its technology for this expanding demand. The PORTO unit combines robust design and functionality, ensuring efficient delivery capabilities.
Medigus Ltd. (Nasdaq: MDGS) announced the appointment of Prof. Nancy Agmon-Levin to the scientific advisory board of Polyrizon Ltd., a company in which Medigus holds a 37.03% stake. Prof. Agmon-Levin is a noted expert in immunology and allergy, currently leading the Clinical Immunology Unit at Sheba Medical Center in Israel. This addition aims to enhance Polyrizon's capabilities in addressing autoimmune diseases and allergies. Prof. Agmon-Levin joins a board already featuring renowned experts in biomaterials and drug delivery.
FAQ
What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?
What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?
